Merck
  • Home
  • Search Results
  • Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.

Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.

Annals of hematology (2014-04-02)
Paul Roda, Ashley Ferrari, Xiaoqin Tang, Porat Erlich, Cindy Eisenhower, Megha D Patel, Elizabeth Ann Irvin-Barnwell
ABSTRACT

In 2005, three independent research groups described the presence of a specific mutation in the JAK2 gene, JAK2V617F, in patients with a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN). The percentage of patients with the mutation varied according to specific disease with >98 % of polycythemia vera (PV) patients having the mutation. In 2008, the World Health Organization issued new diagnostic criteria for PV including use of the JAK2V617F test as a major diagnostic criterion. The goal of the present study is to determine the accuracy of diagnosing PV in a community practice and reporting of PV to cancer registries, as well as assessing the integration of molecular testing into diagnostic paradigms. Using Geisinger Medical Center's electronic medical records (EMR), patients with a PV diagnosis being seen by a hematologist/oncologist during 2004-2009 were identified. Records were reviewed by a single hematologist/oncologist to determine accuracy of the treating physician's diagnosis and use of the molecular test for the JAK2V617F mutation. There was a diagnosis of PV from the treating physicians in 121 of the 204 evaluable patients (59 %) and another MPN in 21 (10 %). However, we confirmed a PV diagnosis in only 90 patients (44 %). Of the 90 confirmed PV patients, 64 were JAK2V617F-mutation positive while 24 were not tested. While JAK2V617F testing has made a major impact in facilitating the successful delineation of the type of polycythemia (PV versus secondary polycythemia) in patients evaluated in a large, community-based Hematology/Oncology practice, physician usage of other critical tests is inconsistent leading to errors in diagnosis. JAK2V617F mutation testing in combination with other diagnostic criteria may help reduce diagnostic errors.

MATERIALS
Product Number
Brand
Product Description

Valine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-Valine, reagent grade, ≥98% (HPLC)
Supelco
L-Valine, certified reference material, TraceCERT®
Sigma-Aldrich
L-Valine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
SAFC
L-Valine
Sigma-Aldrich
L-Valine, BioUltra, ≥99.5% (NT)
Supelco
L-Valine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Phenylalanine, 99%, FCC
Supelco
L-Phenylalanine, Pharmaceutical Secondary Standard; Certified Reference Material
USP
L-Phenylalanine, United States Pharmacopeia (USP) Reference Standard
Phenylalanine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-Phenylalanine, reagent grade, ≥98%
Sigma-Aldrich
L-Phenylalanine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L-Phenylalanine, BioUltra, ≥99.0% (NT)
Supelco
L-Phenylalanine, analytical standard, for Nitrogen Determination According to Kjeldahl Method
Supelco
L-Phenylalanine, certified reference material, TraceCERT®